INTRODUCTION {#sec1}
============

The seasonal influenza vaccine is widely used within the United Kingdom to provide protection against the influenza virus. Several rare autoimmune phenomena, including vasculitis, have been widely reported following its administration, and to date, a causal relationship between influenza vaccine and vasculitis has not been established \[[@ref1]\]. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is one of several vasculitides that has occurred in temporal relationship with the influenza vaccine \[[@ref2], [@ref3]\]. AAV is a rare, small-vessel vasculitis that refers to three syndromes: granulomatosis with polyangiitis (GPA), microscopic polyangiitis and eosinophilic GPA \[[@ref4]\]. In Europe, the annual incidence is 13--20 cases per million individuals and it can lead to a rapidly progressive necrotizing glomerulonephritis \[[@ref5]\]. Several reports have documented development or relapse of AAV following administration of the influenza vaccine \[[@ref2], [@ref3]\].

Anti-glomerular basement membrane (Anti-GBM) disease is another rare small-vessel vasculitis that occurs at an annual incidence of one case per million population \[[@ref6]\]. Co-presentation with ANCA and anti-GBM antibodies represents double seropositive vasculitis, which accounted for up to 50% of patients presenting with anti-GBM in one cohort \[[@ref7]\]. Outcomes in double seropositive vasculitis are variable and represent a mixture between the clinical courses of both vasculitides. Here, we report a novel case of double seropositive vasculitis following seasonal influenza vaccination, which to the best of our knowledge, has never been reported.
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CASE REPORT {#sec2}
===========

A 72-year-old Caucasian male retired engineer, with no significant medical or surgical history, presented with a 4-week history of general malaise, myalgia and fevers. Four weeks before presentation, he received the inactivated influenza vaccination in primary care. Four days following vaccination, he became generally unwell and visited his general practitioner on two occasions over 14 days. He was initially prescribed a co-amoxiclav course for a presumed lower respiratory tract infection, followed by a course of doxycycline. There was no history of haemoptysis but he did develop visible haematuria. He had no regular medications, no family history and was an otherwise well ex-smoker (50 pack/years) who played golf regularly with no recent foreign travel. Due to persistent symptoms, he underwent blood tests that revealed a creatinine of 684 micromol/L, which prompted referral to secondary care.

On presentation to hospital, his physical examination was normal and his initial investigations are shown in Table [1](#TB1){ref-type="table"}. Briefly, these showed raised inflammatory markers, a positive urine dip (Blood 3^+^, protein 2^+^) and stage three acute kidney injury (AKI) with a Birmingham Vasculitis Activity Score of 14. An urgent ultrasound revealed normal sized kidneys without evidence of obstruction. However, it did show a large abdominal aortic aneurysm (AAA). He subsequently underwent computed tomography aortogram showing a seven-centimetre infra-renal AAA with no evidence of leak. He was admitted to the renal ward where his renal function continued to deteriorate with a peak creatinine of 768 micromol/L. Urgent immunological tests showed ANCA positive with MPO antibodies of 74 U/ml and anti-GBM positive with antibodies of 53 U/mL. He was initiated on haemodialysis via temporary vascath and was given high-dose intravenous methylprednisolone (500 mg) for two consecutive days. Concurrently, he underwent an ultrasound-guided renal biopsy consistent with double seropositive vasculitis (Fig. [1](#f1){ref-type="fig"}). Three days following presentation, he started seven rounds of plasma exchange over a 10-day period and was inducted with oral cyclophosphamide (100 mg) before starting 'CYCLOPS', which is the induction/consolidation regimen using pulsed cyclophosphamide for AAV.

###### 

Results summary of the investigations performed on the patient in secondary care

  --
  --

He remained dialysis-dependent during admission and received a tunnelled line to continue intermittent dialysis on discharge. An early multidisciplinary decision was made to hold off intervention for the AAA until completion of treatment for vasculitis. He was successfully discharged and continued to receive cyclophosphamide as an outpatient, showing good renal recovery following treatment (creatinine 321 micromol/L). Nine months following the acute episode, he successfully underwent an elective three-vessel fenestrated endovascular aortic repair without need for renal replacement therapy.

DISCUSSION {#sec3}
==========

In this report, we described a patient who developed double seropositive vasculitis within four weeks of influenza vaccine administration. Previous reports describe development of AAV in association with the influenza vaccine, but to the best of our knowledge, this is the first reported case associated with double seropositive vasculitis.

Multiple reports document the development of vasculitis following administration of the influenza vaccine but a causal relationship has yet to be concluded \[[@ref1]\]. The aetiology of post-influenza vaccination vasculitis is currently unknown, although several hypotheses have been postulated. The influenza vaccine contains inactivated preparations of immunogenic antigens representative of influenza viruses. Therefore, it has been suggested that molecular mimicry, whereby a foreign antigen shares structural similarities with self-antigens, could be implicated in development of this autoimmune phenomena \[[@ref8]\]. Other hypotheses focus on vaccine adjuvants and how they may lead to post-vaccination adverse reactions known as 'autoimmune syndrome induced by adjuvants' \[[@ref9]\]. Like post-influenza vaccination vasculitis, the aetiology of AAV remains unclear with many postulating roles for infectious, genetic and/or environmental factors \[[@ref10]\].

In double seropositive vasculitis, the clinical course is variable and it has been suggested outcomes reflect the severity of the presentation rather than actual diagnosis. It has been postulated that the predominant older age of onset, longer prodromal illness and high propensity to renal recovery suggests ANCA-mediated glomerular inflammation may precede, and be the driver for, development of anti-GBM disease \[[@ref7]\]. Therefore, we hypothesize that administration of the influenza vaccine in our case may have caused an immunological response that stimulated an inflammatory process leading to double seropositive vasculitis and AKI. Alternatively, the older age of onset and more prolonged prodromal illness could represent prior ANCA-mediated glomerular inflammation with subsequent superimposed anti-GBM disease with vaccination a triggering event. Regarding the AAA, the most likely explanation is a pre-existing aneurysm in a patient with cardiovascular risk factors. However, we cannot exclude accelerated aneurysmal growth as a sequela of the pro-inflammatory response following vaccination.

Ultimately, the temporal association of influenza vaccination with double seropositive vasculitis may suggest a trigger for development of vasculitis in susceptible individuals. Further studies are needed to characterize and confirm the mechanism of post-influenza vasculitis. Clinicians should be drawn to the rare possibility of vasculitis as a cause of unexplained symptom complexes following influenza vaccination.
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